Sun Chuan Dai, MD
Gastroenterology · Philadelphia, PANPI 1811157050
Payments from drug & device makers
Across 63 payments — averaging $491.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$25K
- Olympus Medical Systems Corporation$4K
- Fujifilm Healthcare Americas Corporation$1K
- Olympus America Inc.$305
- 3-d Matrix, Inc.$182
- Creo Medical Inc.$166
- plus $446 from 5 others
What the payments were for
- Consulting fees$3,63412%
- Speaking & faculty fees$20,40066%
- Travel & lodging$2,2777%
- Food & beverage$4,63815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 39 | $24,832 |
| Olympus Medical Systems Corporation | 1 | $3,634 |
| Fujifilm Healthcare Americas Corporation | 10 | $1,383 |
| Olympus America Inc. | 4 | $305 |
| 3-d Matrix, Inc. | 1 | $182 |
| Creo Medical Inc. | 1 | $166 |
| ERBE USA Inc | 1 | $140 |
| AbbVie | 2 | $102 |
| Omega Medical Imaging, LLC | 2 | $78 |
| Cook Medical LLC | 1 | $68 |
| Pentax Of America, Inc. | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVIS EXERA II SMALL INTESTINAL VIDEOSCOPE$3,634
- AXIOS$1,159
- FUJIFILM$1,102
- GENERAL - BILIARY DEVICES$273
- Creo Medical$166
- SPYGLASS$155
- Erbe VIO3$140
- EVIS EXERA III COLONOVIDEOSCOPE$105
- ACQUIRE$102
How this compares
$30,949 in reported general payments places this provider in the 85th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 12 | $4,701 |
| Pantoprazole Sodium | 14 | $250 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Philadelphia
- Kuchikala ReddyPhiladelphia$6.5M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
- Gary WuPhiladelphia$931K
- Faten AberraPhiladelphia$909K
- Ben StangerPhiladelphia$815K
- David KaplanPhiladelphia$737K
- Stacey PrennerPhiladelphia$577K
- Mark OstermanPhiladelphia$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.